

10/518,007

=> d his

(FILE 'HOME' ENTERED AT 13:49:37 ON 16 NOV 2006)

FILE 'REGISTRY' ENTERED AT 13:49:58 ON 16 NOV 2006

L1 STRUCTURE UPLOADED

L2 2 S L1

L3 8 S L1 FULL

FILE 'HCAPLUS, CHEMCATS' ENTERED AT 13:50:50 ON 16 NOV 2006

L4 2 S L3

FILE 'HCAPLUS, HCAOLD, USPATFULL, EPFULL, BIOSIS, MEDLINE' ENTERED AT
13:51:47 ON 16 NOV 2006

L5 188036 S BENZOIC ACID? OR BENZOIC ACID DERIVATIVE?

L6 103714 S L5 AND ?AMINO?

L7 680313 S DIABETES OR INSULIN RESISTANCE OR PEROXISOME PROLIFERATOR-ACT

L8 10162 S L6 AND L7

L9 4662 S L8 AND LIPID?

L10 4647 S L9 AND (PHARMACEUTICAL OR TREAT? OR COMPOSITION)

L11 4406 S L10 AND (SALT OR PRODRUG)

L12 3284 S L11 AND (OXY OR SULFUR OR SULFONYL)

L13 901 S L12 AND ORTHO

L14 508 S L13 AND (PHENOXY OR OXOETHYL OR OXOPROPYL)

L15 487 S L14 AND BENZYL


10/518,007

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



G1 X,Cb,Cy,Hy,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 15:23:43 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 138 TO ITERATE

100.0% PROCESSED 138 ITERATIONS
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 2056 TO 3464
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 15:23:46 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 3141 TO ITERATE

100.0% PROCESSED 3141 ITERATIONS
SEARCH TIME: 00.00.01

0 ANSWERS

L3 0 SEA SSS FUL L1

=>


10/518,007

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



G1 O,S

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 13:50:17 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 8 TO ITERATE

100.0% PROCESSED
SEARCH TIME: 00.00.01

8 ITERATIONS

2 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 8 TO 329
PROJECTED ANSWERS: 2 TO 124


L2 2 SEA SSS SAM L1

=> d scan

L2 2 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN Benzoic acid, 2-[[[4-[2-[ethyl[[4-(trifluoromethyl)phenyl]methyl]amino]-2-oxoethyl]phenyl]thio]methyl]- (9CI)

MF C26 H24 F3 N O3 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 2 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN Benzoic acid, 2-[[[4-[2-[hexyl(phenylmethyl)amino]-2-oxoethyl]-2-

methoxyphenoxy]methyl] - (9CI)
MF C30 H35 N O5




ALL ANSWERS HAVE BEEN SCANNED

```
100.0% PROCESSED          74 ITERATIONS                      8 ANSWERS
SEARCH TIME: 00.00.01
```

=> d scan


L3 8 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzoic acid, 2-[[4-[2-[ethyl[(2-fluorophenyl)methyl]amino]-2-
oxoethyl]phenoxy]methyl]- (9CI)
MF C25 H24 F N O4



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):7


L3 8 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzoic acid, 2-[[4-[2-[hexyl(phenylmethyl)amino]-2-oxoethyl]-2-
methoxyphenoxy]methyl]- (9CI)
MF C30 H35 N O5

10/518,007




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 8 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzoic acid, 2-[[4-[2-[[[(2,4-difluorophenyl)methyl]heptylamino]-2-oxoethyl]phenoxy]methyl]- (9CI)
MF C30 H33 F2 N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 8 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzoic acid, 2-[[[4-[2-[[[(4-chlorophenyl)methyl]ethylamino]-2-oxoethyl]phenyl]thio]methyl]- (9CI)
MF C25 H24 Cl N O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 8 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzoic acid, 2-[[[4-[2-[[[(2,4-difluorophenyl)methyl]heptylamino]-2-oxoethyl]phenyl]thio]methyl]- (9CI)
MF C30 H33 F2 N O3 S

10/518,007




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 8 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Benzoic acid, 2-[[[4-[2-[ethyl[[4-(trifluoromethyl)phenyl]methyl]amino]-2-oxoethyl]phenyl]thio]methyl]- (9CI)
 MF C26 H24 F3 N O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 8 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Benzoic acid, 2-[[[4-[2-[hexyl(phenylmethyl)amino]-2-oxoethyl]phenoxy]methyl]- (9CI)
 MF C29 H32 F N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 8 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN Benzoic acid, 2-[[[4-[2-[hexyl(phenylmethyl)amino]-2-oxoethyl]phenoxy]methyl]- (9CI)
 MF C29 H33 N O4

10/518,007



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file hcaplus chemcat

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

166.94

167.15

FILE 'HCAPLUS' ENTERED AT 13:50:50 ON 16 NOV 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CHEMCATS' ENTERED AT 13:50:50 ON 16 NOV 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

=> s l3

L4 2 L3

=> d 1-2 ibib abs hitstr

L4 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:2838 HCAPLUS

DOCUMENT NUMBER: 140:41910

TITLE: Preparation of ortho-substituted benzoic acid derivatives for the treatment of insulin resistance

INVENTOR(S): Li, Lanna

PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.

SOURCE: PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000790	A1	20031231	WO 2003-GB2584	20030617
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

CA 2489834	AA	20031231	CA 2003-2489834	20030617
CA 2489834	C	20061003		
AU 2003240099	A1	20040106	AU 2003-240099	20030617
BR 2003011932	A	20050322	BR 2003-11932	20030617
EP 1517883	A1	20050330	EP 2003-732713	20030617
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1675171	A	20050928	CN 2003-819474	20030617
JP 2005529970	T2	20051006	JP 2004-515007	20030617
JP 3782818	B2	20060607		
NO 2004005353	A	20050120	NO 2004-5353	20041207
US 2005256198	A1	20051117	US 2004-518007	20041214
ZA 2004010161	A	20051020	ZA 2004-10161	20041215
JP 2006182782	A2	20060713	JP 2006-19068	20060127
PRIORITY APPLN. INFO.:			SE 2002-1935	A 20020620
			SE 2002-3826	A 20021220
			JP 2004-515007	A3 20030617
			WO 2003-GB2584	W 20030617

OTHER SOURCE(S): MARPAT 140:41910
GI



AB Title compds. I [$n = 0-2$; $R_1 = \text{halo, alkyl, alkoxy, etc.}$; $R_2 = \text{alkyl}$; $Y = \text{absent, CH}_2$; $X = O, S$] are prepared For instance, N-benzyl-N-hexyl-3-(4-hydroxyphenyl)propanamide (preparation given) is reacted with Me 2-(bromomethyl)benzoate (CH_3CN , K_2CO_3 , 66°) and the product saponified ($\text{THF}/\text{H}_2\text{O}$, LiOH , microwave, 120° , 40 min) to give II. Example compds. have $\text{EC}_{50} < 50 \mu\text{mol/L}$ for PPAR- α . I are useful for treating clin. conditions associated with insulin resistance.

IT 637015-02-2P, 2-[[[4-[2-[(2,4-Difluorobenzyl) (heptyl)amino]-2-oxoethyl]phenyl]thio]methyl]benzoic acid 637015-05-5P, 2-[[[4-[2-[Benzyl (hexyl)amino]-2-oxoethyl]phenoxy]methyl]benzoic acid 637015-07-7P, 2-[[[4-[2-[(2,4-Difluorobenzyl) (heptyl)amino]-2-oxoethyl]phenoxy]methyl]benzoic acid 637015-32-8P, 2-[[[4-[2-[Ethyl[4-(trifluoromethyl)benzyl]amino]-2-oxoethyl]phenyl]thio]methyl]benzoic acid 637015-33-9P, 2-[[[4-[2-[Ethyl(2-fluorobenzyl)amino]-2-oxoethyl]phenoxy]methyl]benzoic acid 637015-40-8P, 2-[[[4-[2-[(4-Chlorobenzyl) (ethyl)amino]-2-oxoethyl]phenyl]thio]methyl]benzoic acid

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU


10/518,007

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(ortho-substituted benzoic acid derivs. for treatment of insulin resistance)


RN 637015-02-2 HCAPLUS

CN Benzoic acid, 2-[[[4-[2-[[2,4-difluorophenyl)methyl]heptylamino]-2-oxoethyl]phenyl]thio]methyl]- (9CI) (CA INDEX NAME)




RN 637015-05-5 HCAPLUS

CN Benzoic acid, 2-[[[4-[2-[hexyl(phenylmethyl)amino]-2-oxoethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)




RN 637015-07-7 HCAPLUS

CN Benzoic acid, 2-[[[4-[2-[[2,4-difluorophenyl)methyl]heptylamino]-2-oxoethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 637015-32-8 HCAPLUS


CN Benzoic acid, 2-[[[4-[2-[ethyl[[4-(trifluoromethyl)phenyl]methyl]amino]-2-oxoethyl]phenyl]thio]methyl]- (9CI) (CA INDEX NAME)



RN 637015-33-9 HCAPLUS


10/518,007

CN Benzoic acid, 2-[[4-[2-[ethyl[(2-fluorophenyl)methyl]amino]-2-oxoethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 637015-40-8 HCAPLUS

CN Benzoic acid, 2-[[[4-[2-[[[4-chlorophenyl)methyl]ethylamino]-2-oxoethyl]phenyl]thio]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:2679 HCAPLUS

DOCUMENT NUMBER: 140:76898

TITLE: Preparation of benzoic acid derivatives as modulators of PPAR- α and PPAR- γ

INVENTOR(S): Li, Lanna

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 101 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000295	A1	20031231	WO 2003-GB2598	20030617
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2490687	AA	20031231	CA 2003-2490687	20030617
AU 2003240101	A1	20040106	AU 2003-240101	20030617
BR 2003011840	A	20050315	BR 2003-11840	20030617
EP 1517680	A1	20050330	EP 2003-732715	20030617
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1662230	A	20050831	CN 2003-814319	20030617

JP 2006502105	T2	20060119	JP 2004-515010		20030617
NZ 536972	A	20060630	NZ 2003-536972		20030617
NO 2004005222	A	20050119	NO 2004-5222		20041129
ZA 2004009690	A	20051011	ZA 2004-9690		20041130
US 2005267149	A1	20051201	US 2004-518819		20041220
PRIORITY APPLN. INFO.:			SE 2002-1937	A	20020620
			WO 2003-GB2598	W	20030617
OTHER SOURCE(S):		MARPAT 140:76898			
GI					




AB Title compds. I [R1 = (un)substituted aryl, alkyl, acyl, etc.;
(CH2)m-T-(CH2)n-U-(CH2)p = attached at either the meta or para position
(to V) and is O(CH2)2, O(CH2)3, etc.; V = O, S, amino, single bond; q =
1-3; W = O, S, amido, amino, single bond; R2 = halo, alkyl, alkoxy, etc.;
r = 0-3; R3 = halo, alkyl, alkoxy, etc.; s = 0-3; with some provisions]
are prepared For instance, tert-Bu [3-[[[(1,1'-biphenyl-4-
yl)carbonyl]amino]methyl]phenyl]carbamate (preparation given) is deprotected
(CH2Cl2, TFA) and alkylated with 3-carboxybenzaldehyde (HOAc, NaBH4) to
give II. Compds. of the invention have an EC50 < 50µmol/L for
PPAR-α and PPAR-γ. I are useful in treating clin. conditions
associated with insulin resistance.

IT 637358-56-6P, 2-[[[4-[2-[Benzyl(hexyl)amino]-2-oxoethyl]-2-
fluorophenoxy]methyl]benzoic acid 637358-59-9P,
2-[[[4-[2-[Benzyl(hexyl)amino]-2-oxoethyl]-2-methoxyphenoxy]methyl]benzoic
acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of benzoic acid derivs. as modulators of PPAR-α and
PPAR-γ)

RN 637358-56-6 HCAPLUS


10/518,007

CN Benzoic acid, 2-[[2-fluoro-4-[2-[hexyl(phenylmethyl)amino]-2-oxoethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 637358-59-9 HCAPLUS

CN Benzoic acid, 2-[[4-[2-[hexyl(phenylmethyl)amino]-2-oxoethyl]-2-methoxyphenoxy]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT